Appeal No. 94-1696
Application 07/811,129
6), etc., which teach the cloning and expression of ICAM-1 or
ICAM-2 would “read on” the products described in claims 1 through
8. That is, it is not clear whether references which teach
purified ICAM-1 or ICAM-2 “read on” soluble molecules having (i)
a first region which is capable of binding LFA-1 or
“substantially corresponding to an extracellular portion of ICAM-
2," and (ii) a second region “substantially corresponding to an
immunoglobulin constant region.
Any request for reconsideration or modification of this
decision by the Board of Patent Appeals and Interferences based
upon the same record must be filed within one month from the date
of the decision (37 CFR § 1.197). Should appellant[s] elect to
have further prosecution before the examiner in response to the
new rejection under 37 CFR § 1.196(b) by way of amendment or
showing of facts, or both, not previously of record, a shortened
statutory period for making such response is hereby set to expire
two months from the date of this decision.
16
Page: Previous 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next
Last modified: November 3, 2007